Prior approval for the use of remdesivir by Gilead in the treatment of patients with COVID-19 may be issued in the coming days, Reuters reported.

“It might be that a conditional market(ing) authorisation can be issued in the coming days,” the head of the European Union’s medicines agency Guido Rasi said on Monday at a hearing in the EU Parliament in Brussels.

EMA has already recommended the use of remdesivir in exceptional circumstances, which allows patients to prescribe the drug before final approval is obtained.